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without saxagliptin, which increased by US$2,812,671 during this period, reaching 
US$77,249,307 in year 3. Total costs in scenario with saxagliptin, however, remained 
stable around US$74,000,000/year. Introduction of saxagliptin is expected to be 
economical to the PHS, with savings of US$3,048,812 in year 3. Annual savings per 
patient potentially impacted by the introduction of saxagliptin correspond to 8% of 
pharmaceutical costs at year 3. Sensitvity analysis demonstrated that saxagliptin price 
is the most impactful parameter in the model, and a 25% increase over its price would 
still generate savings around US$2,100,000 to the PHS. CONCLUSIONS: Introduc-
tion of saxagliptin as a therapeutic option to patients with T2D in the PHS will save 
around US$4,900,000 in the next three years.
PDB14
BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF 
SAXAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES IN 
ARGENTINA
Elgart J1, Caporale J1, Gagliardino JJ1, Waschbusch M2, Aiello EC2, Jotimliansky L2
1National University of La Plata, La Plata, Buenos Aires, Argentina, 2Bristol-Myers Squibb, 
Buenos Aires, Argentina
OBJECTIVES: To estimate the budget impact of saxagliptin introduction as a treat-
ment option for patients with type 2 diabetes mellitus (DM2), compared to the present 
situation. METHODS: An MS Excel-based budget impact model assuming coverage 
for one million people. The time horizon was three years and the analysis perspective 
was a social security organization in Argentina. Pharmaceutical expenses of antidia-
betic agents were analyzed excluding other medical costs. The cost of antidiabetic 
agents was based upon the consumer price index adjusted to copayments and dis-
counts (2009); the saxagliptin price was considered to be equal to the sitagliptin price. 
The market share of the different drugs was based upon market studies and data 
provided by Bristol Myers Squibb. The budget impact is reported in terms of annual 
treatment costs and monthly costs per member per month (PMPM). Finally, a one-way 
sensitivity analysis was carried out. RESULTS: The net budget impact estimated for 
the introduction of saxagliptin was US$2.077 for the ﬁrst year, US$4.377 for the 
second year and US$9.230 for the third year; the accumulated net budget impact was 
US$15.648. The PMPM result was US$0.0002, U$$0.0004 and US$0.0008 for each 
year respectively. The accumulated impact in the total annual budget for antidiabetics 
was 0.07%. DM2 prevalence changes ± 50% derived an accumulated net budget 
impact of US$23.526 to US$7.842; a slight saxagliptin price decrease (-2%) generates 
a negative budget impact of US$538, US$1.133 and US$2.390 for each year respec-
tively. CONCLUSIONS: The budget impact of adding saxagliptin in a population of 
one million afﬁliates of the Argentinean social security is minimal in patients with 
DM2.
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OBJECTIVES: Hyperglycemia in the hospital setting is associated with increased 
adverse outcomes and costs. The objective of this study was to assess three insulin 
infusion protocols, conventional sliding scale (CSS) protocol, intensive insulin treat-
ment (IIT) protocol, and basal insulin infusion (BII) protocol in critically-ill patients 
of a surgical intensive care unit (SICU). METHODS: This observational, retrospective, 
cohort study examined adult patients admitted to the SICU between January-October 
2007. Clinical measures and total SICU charges were evaluated for patients admitted 
over 48 hours. When patients had two consecutive blood glucose (BG) levels >200 mg/
dL the CSS protocol was initiated. The BII protocol was initiated when two consecu-
tive BG levels were between 121 and 150 mg/dL, and the IIT protocol was initiated 
when BG was >150 mg/dL. Descriptive, one-way analysis of variance and chi square 
analysis were conducted. RESULTS: The cohort of 112 patients was extracted (24 
BII, 29 IIT, and 49 CSS). No signiﬁcant differences in age, race, gender, BMI, admis-
sion diagnosis and receipt of vasopressors, steroids or antibiotics were found among 
groups. There were no signiﬁcant differences in mean (SD) SICU costs between groups 
[CSS: $97,880 ($114,729); BII: $119,007 ($111,791); IIT: $161,876, ($222,286)]. 
Number of patients who experienced hypoglycemia (BG < 60 mg/dL) were signiﬁ-
cantly higher in the IIT group compared to the BII and CSS groups (58.6%, 41.7% 
and 22.0%, respectively, p = 0.001). More patients were mechanically-ventilated in 
the IIT group compared to the BII and CSS groups (75.9%, 66.7% and 33.9%, 
respectively, p = 0.001). No signiﬁcant differences were found in SICU and hospital 
mortality rates, SICU and hospital length of stays, and blood transfusion receipt, 
among the three groups. CONCLUSIONS: The basal insulin infusion protocol can 
reduce adverse events like hypoglycemia and mechanical ventilation with no signiﬁcant 
changes in SICU costs compared to intensive or sliding scale insulin therapies.
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OBJECTIVES: Insulin in infusion sets and reservoirs is discarded periodically based 
upon the stability of the insulin product. Following a label change regarding the stabil-
ity of Novolog (insulin aspart) from two days to six, we modeled the differential in 
discarded insulin volume and computed the total annual insulin and pump supply 
costs from a US health plan perspective. METHODS: A model was developed to 
calculate the discarded insulin volume under a two-day stability scenario (insulin in 
the infusion set and reservoir discarded after two days) versus six days. A mix of 
insulin pumps of various reservoir capacities was used in the model based upon current 
U.S. market share and a range of daily insulin dosages based on retrospective claims 
data. The cost of the discarded insulin was calculated using the wholesale acquisition 
cost (WAC) of NovoLog. The cost of pump supplies was calculated for the two-day 
scenario assuming a complete infusion set, including reservoir, was required every two 
days. In the six-day scenario a complete infusion set was required every six days and 
a change of cannula at the insertion site midway between complete changes. The WAC 
price of the least expensive supplies for each pump was used to calculate the cost of 
supplies. RESULTS: Based on total U.S. pump usage, a one-million member health 
plan was estimated to have 1180 pump users. The mean annual per patient reduction 
in discarded insulin volume in the six-day scenario, compared to the two-day scenario, 
was 15,656 units at a WAC cost of $1452. The corresponding cost reduction for the 
entire plan was $1,713,751. The reduction in annual supply cost for the plan was 
$1,613,126. CONCLUSIONS: The change in stability from two to six days resulted 
in total annual savings to the health plan in insulin volume and pump supplies of 
$3,326,877.
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OBJECTIVES: To compare the health care cost outcome of a basal insulin regimen 
of long-acting insulin analogs (LAIA) with NPH insulin, in patients with T2D. 
Analysis was based on Danish health care costs. METHODS: Data were extracted 
from Danish national registers covering the entire population of approximately 5 
million people. Included in the analysis were prescription, hospital in- and out-patient 
costs and socioeconomic variables. Patients were identiﬁed during a 1-year index 
period (2005) and allocated to treatment with either LAIA or NPH insulin. Patients 
with type 2 diabetes were identiﬁed with at least one oral antidiabetic drug prescrip-
tion between 1995 and 2007. Basal only patients had fewer than two prescriptions 
of fast-acting insulin were identiﬁed. The patients from the LAIA group (n = 303) 
were matched with patients from the NPH group (n = 8523) with respect to observ-
able variables using propensity scores. Health care costs were analysed for a follow-up 
period of 2 years, maximum. RESULTS: The highest proportion of health care costs 
in both treatment groups could be attributed to in-patient care, accounting for 46% 
and 38% in the NPH and LAIA-groups, respectively. Overall annual health care 
costs however, which included all prescription medicine, amounted to 36230 in the 
NPH group and 5524 in the LAIA group. This difference in total costs between 
treatments groups was not statistically signiﬁcant (p = 0.302). CONCLUSIONS: 
Patients with T2D on a basal insulin regimen using LAIA do not seem to cost more 
in terms of health care resource than patients using NPH insulin. This national study 
is ongoing and is expected to be revised with longer follow-up and more complete 
hospital data.
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OBJECTIVES: In Mexico, the burden of disease from diabetes and related complica-
tions is very high. According to epidemiological estimates, the burden will even 
increase more through time. However, there is minimal information on the disease 
management and usage of health care resources in the private sector, for diabetes. 
This study analyzes the treatment patterns and estimates the costs of treating diabetes 
and its complications from a private health care payer perspective. METHODS: 
Observational, retrospective, study of 1539 patients receiving care for diabetes. Data 
for one year of follow up was extracted from a private insurance database, of patients 
18 years of age and older. Analysis included treatment patterns details of diabetes and 
related complications, description of health care resources utilization and associated 
costs. RESULTS: The total average annual treatment cost per diabetic patient was in 
a range of $800 USD. The most common pharmaceutical scheme used to control 
glucose levels was metformin + sulfonylureas (34%) followed by metformin alone 
(22%). However, of the pharmaceutical expenditure only 26% accounted for glucose 
control, with the remaining designated mainly for treating related complications. The 
highest level of expenditure was due to hospitalizations, utilizing 40% of the total 
budget followed by pharmaceutical expenditures (17%). A total of 57.2% of patients 
had at least one complication and 17.7% two or more. The most frequent complica-
tion was ischemic heart disease, 32% of the patients. Diabetic nephropathy was the 
largest single contributor to the total cost of overall management of complications. 
CONCLUSIONS: In this study we analyzed the treatment patterns and resource use 
of treatment of diabetic patients in the private sector. This data is useful for planning 
of future resource allocation of diabetes care, given the increasing demand of health 
services in the area.
